Veterinary Reference Laboratory Market Worth $5.13 Billion By 2025

The global veterinary reference laboratories (VRL) market is expected to reach USD 5.13 billion by 2025, according to a new report by Grand View Research, Inc. Increase in incidence of zoonotic diseases is a key driving factor for market growth. Increase in adoption of integrated diagnostic systems coupled with information ecosystems for veterinary diagnostics is anticipated to fuel development.

Rise in demand for advanced diagnostic tests and growing awareness amongst consumers are some of the factors expected to boost demand over the coming years. Moreover, companies are investing in R&D for the advancement of test kits for cost-effective diagnosis & monitoring of animal health, which is expected to boost growth. Some of the advancements in this market include efficient information management systems used in animal diagnostic applications, vaccine banks, and mobile apps for continuous monitoring. High focus toward innovation in veterinary health is anticipated to fuel the demand for reference labs. For instance, Innovative Medicines Initiative (IMI) is a public-private partnership that supports pharmaceutical innovations in Europe.

In addition, MediLab Secure, a laboratory network project was established, which aims to identify emerging viruses& pathogens in 19 countries in the Mediterranean regions and 57 labs were involved. Furthermore, increase in the number of government initiatives to promote veterinary diagnostics products is presumed to drive the overall growth.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/veterinary-reference-laboratory-vrl-market

Further Key Findings From the Study Suggest:

The clinical chemistry analyzers segment held the dominant share of the market as of 2016 owing to growing demand for veterinary diagnostics products
Increase in instances of contamination in pet foods that cause severe illnesses and deaths amongst animals is expected to boost the demand for toxicology testing services
Production animals accounted for largest revenue share in 2016 owing to their highest consumption rate
The market was dominated by North America and is expected to retain its position throughout the forecast period
Presence of prominent industry players, advanced healthcare infrastructure, and high healthcare expenditure are some of the factors responsible for growth
Companies offering reference laboratories are focusing on the development of cost-effective diagnostic solutions for animal health
IDEXX Laboratories, Inc. held a dominant share owing to its presence across the globe and a wide product portfolio of advanced diagnostic tests
Strategies such as regional expansion, new product developments, merger & acquisitions, and research collaborations are anticipated to propel growth
For instance, in January 2017, Mars, Inc. announced the agreement for acquiring VCA Inc. in a probe to capture higher share

Latin America In Vitro Diagnostics Market Size To Reach $5.1 Billion By 2024

The latin america IVD market is expected to reach over USD 5.1 billion by 2024, according to a new report by Grand View Research, Inc. The Latin America IVD market is expected to grow at a significant CAGR till 2024 owing to the rising prevalence of target disorders, aging population, and the presence of favorable government initiatives for early disease diagnosis. Other factors that are anticipated to boost the growth include the introduction of technologically advanced instruments and the increasing R&D initiatives for the development of disease-specific kits.

Regular testing for diabetes, cardiovascular, cancer, and sexually transmitted diseases are necessary for the timely treatments, further avoiding the risk of fatal health complications. The availability of tests for home and near patient testing is estimated to further enhance the usage rates of these devices. From November 2015, the Anvisa, which is a regulatory body for medical devices in Brazil, has started allowing the registration for HIV self-testing kits.

The increasing adoption point of care devices coupled with the increasing awareness among the healthcare professionals regarding the early diagnosis of various diseases has provided a boost to the Latin IVD market. The rising epidemic of communicable diseases in the southernpart of Latin America, the growing need for rapid and accurate diagnostics, and the changing healthcare infrastructure scenario are some of the key drivers of the Latin IVD market.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/latin-america-in-vitro-diagnostics-ivd-market

Further key findings from the study suggest:

The instrument segment is one of the most important segments of in vitro diagnostics. The presence of highly automated analyzers and the availability of over the counter products are some of the factors responsible for its significant share.
The Molecular diagnostics segment is anticipated to be the fastest growing technology over the decade. Molecular diagnostics is a transformative area of diagnostics. The continuous innovation in technology helps the physicians for critical decision making
The infectious disease segment held the largest share in 2015 over 24% owing to the presence of favorable government initiatives in association with the WHO to curb communicable diseases.
The home care segment is estimated to witness a significant growth over the forecast period. The high number of R&D initiatives undertaken by key competitors for the development of portable IVD devices with improved sensitivity and user-friendliness is a key factor attributing towards its growth.
In 2015, Brazil was the largest regional segment with a revenue generation of over USD 1.2 billion owing to the established healthcare infrastructure, growing awareness for cancer screening, and the increasing demand for genetic testing.
Peru is expected to be one of the fastest growing regions on account of the growing economic stability, high unmet clinical needs, and the rising disposable incomes
Key players operating in the Latin America IVD market are Roche Diagnostics, Abbott Laboratories, Inc., Hologic (Gen-Probe), Becton Dickinson (BD) Company, Alere, Inc., Bio-Rad Laboratories, Qiagen N.V., Inc., bioMerieux, BioQuidel Corporation, and Siemens Healthcare.

North America PoC Diagnostics Market Worth $8.95 Billion By 2024

The North America point of care diagnostics market is anticipated to reach USD 8.95 billion by 2024, according to a new report by Grand View Research, Inc. Incorporation of advanced information technology solutions coupled with the launch of innovative POC products with automation and ease of use is projected to influence market progression during the forecast period.

Moreover, the rising adoption rate of the POC devices in order to obtain quick results for immediate decision making for patient management is expected to provide the market with lucrative growth avenues. Additionally, the regulatory initiatives introduced for patient care management and rising prevalence of various diseases is attributive to boost demand for these products in the coming years.

The presence of a favorable funding environment in the region is attributive to drive R&D in academic organizations and universities thereby resulting to industrial progress through to 2024.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/north-america-point-of-care-poc-diagnostics-market

Further key findings from the report suggest:

Glucose testing accounted for the largest share of over 41% of the market in 2015 with respect to revenue generation. Factors attributive for the estimated large share includes presence of comprehensive product portfolio provided by the local as well as international market participants. Moreover, rise in the prevalence of diabetes in chronic patients and need for monitoring glucose levels is also supportive for revenue generation of this segment.
Infectious diseases point-of-care tests are expected to witness the fastest growth in the coming years owing to the R&D carried out in this segment for an introduction of novel tests. Infectious disease testing segments include kits for various diseases such as HIV, HBV, respiratory syncytial virus (RSV), pneumonia or streptococcus associated infections, HPV, influenza/flu, HCV, MRSA, Clostridium difficile, TB &drug-resistant TB, and HSV.
Cardiac markers are also anticipated to register substantial growth as a result of an increase in incidence rate of cholesterol associated disorders and rise in the number of cases of congestive heart failure.
Clinics dominated the POC diagnostic market in 2015 due to higher usage of these tests in clinics. However, home settings for POC diagnostics are anticipated to witness the fastest growth owing to rising usage of home health care settings for disease monitoring in the geriatric population.
Assisted living healthcare facilities are also anticipated to witness considerable growth during the forecast period due to the property of rapid diagnostic products to enable simple usage at primary care level and in remote settings even with no laboratory infrastructure
Prominent players of this industry include Qiagen N.V., Spectral Diagnostics, Abbott Laboratories, Siemens Healthcare, Instrumentation Laboratory, Danaher Corporation, BioMerieux, Johnson & Johnson, Abaxis Inc., Roche Diagnostics, Alere Inc., Nova Biomedical, Nipro Diagnostics, and Trinity Biotech.
Strategies adopted by the market players include mergers and acquisitions with the smaller entities operating in market for enhancement of the product portfolio. The participants are involved introduction of new solutions, and collaborations with heath care institutions in order to maintain their global presence.